Ultra-sensitive NGS-based liquid biopsy technology in CDx
QIAGEN and Sysmex Inostics have recently announced a global alliance for the development and commercialization of cancer companion diagnostics (CDx). The partnership capitalizes on Sysmex Inostics’ Plasma-Safe-SeqS (SafeSEQ), an ultra-sensitive next generation sequencing (NGS) liquid biopsy technology and leverages QIAGEN’s experience in developing and commercializing companion diagnostics.
Learn more about:
Embracing opportunity through the QIAGEN-Sysmex partnership
The Power of SafeSEQ: Technology and performance overview
Realizing the clinical value of ultra-sensitive technology